Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

CTSO has been the topic of a number of other reports. HC Wainwright reiterated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $1.24 on Friday. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $2.15. The company’s 50 day moving average price is $1.05 and its two-hundred day moving average price is $0.94. The firm has a market cap of $67.34 million, a PE ratio of -2.10 and a beta of 0.50. The company has a quick ratio of 1.71, a current ratio of 2.12 and a debt-to-equity ratio of 0.82.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same quarter last year, the company earned ($0.14) EPS. Equities research analysts predict that Cytosorbents will post -0.32 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Several hedge funds and other institutional investors have recently made changes to their positions in CTSO. Key Client Fiduciary Advisors LLC boosted its position in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares in the last quarter. CM Management LLC increased its holdings in Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares in the last quarter. Sargent Investment Group LLC raised its position in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Avenir Corp boosted its stake in shares of Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after purchasing an additional 121,294 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in shares of Cytosorbents by 19.9% during the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 299,103 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.